Evolution of the Average Target: Leidos Holdings, Inc.

Evolution of the Target Price: Leidos Holdings, Inc.

Changes in Analyst Recommendations: Leidos Holdings, Inc.

995dd4cbea97cfcd9e2e71e71425e.nKu9sKvJIFDIddgw4p5eQ3k4GFZFumGDKX_95HfAcZY.3vPQ2PmIYjKCQL5Bis4GFRAMIRcaywnGZQqOrD2XFfXJnMfj3p1zEpEtkQ~9ea6065bc726d2d3191a453d79df84a8
08-13 Citigroup Adjusts Price Target on Leidos Holdings to $161 From $138, Keeps Buy Rating MT
08-12 Goldman Sachs Adjusts PT on Leidos Holdings to $132 From $152, Keeps Neutral Rating MT
08-10 Citigroup Adjusts Price Target on Leidos Holdings to $161 From $138, Keeps Buy Rating MT
08-10 Jefferies Adjusts Price Target on Leidos Holdings to $145 From $110, Maintains Hold Rating MT
08-05 Leidos Portfolio Diversification Seen Underappreciated, RBC Says MT
08-05 BNP Paribas Adjusts Leidos Holdings Price Target to $175 From $165 MT
08-05 UBS Adjusts Price Target on Leidos Holdings to $138 From $124, Maintains Neutral Rating MT
08-05 RBC Adjusts Price Target on Leidos to $170 From $180, Maintains Outperform Rating MT
08-05 Stifel Adjusts Price Target on Leidos Holdings to $142 From $193, Maintains Hold Rating MT
08-05 Baird Adjusts Price Target on Leidos Holdings to $150 From $125, Maintains Neutral Rating MT
07-17 Wells Fargo Adjusts Leidos Price Target to $120 From $165, Maintains Equal Weight Rating MT
07-13 Goldman Sachs Adjusts Leidos Price Target to $152 From $171, Maintains Neutral Rating MT
07-13 JPMorgan Adjusts Price Target on Leidos to $160 From $210, Maintains Overweight Rating MT
07-13 Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth… Zonebourse
07-10 Baird Adjusts Price Target on Leidos to $125 From $195 MT
07-10 Truist Cuts Price Target on Leidos Holdings to $160 From $195, Keeps Buy Rating MT
07-10 Analyst recommendations: Cubesmart, Fox Corporation, AMD, Crowdstrike, Micron… Zonebourse
07-07 TD Cowen Adjusts Price Target on Leidos Holdings to $115 From $160 MT
07-07 Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two… Zonebourse
07-01 Jefferies Adjusts Price Target on Leidos Holdings to $110 From $140, Keeps Hold Rating MT
07-01 Citigroup Adjusts Price Target on Leidos Holdings to $138 From $178, Maintains Buy Rating MT
06-30 UBS Adjusts Price Target on Leidos to $124 From $204, Maintains Neutral Rating MT
06-26 Argus Adjusts Price Target on Leidos Holdings to $180 From $225, Maintains Buy Rating MT
06-17 Leidos' Healthcare Business Sees Limited Future Upside From Increasing Competition, BofA Securities Says MT
06-17 BofA Securities Downgrades Leidos to Neutral From Buy, Cuts Price Target to $125 From $200 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+6.79%
+4.2%
-6.55%
+1.25%
+4.03%
+34.25%
+2.74%
+14.87%
+19.88%
-7.51%
Average +7.40%
Weighted average by Cap. +5.32%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
143.83USD
Average target price
153.60USD
Spread / Average Target
+6.79%
High Price Target
225.00USD
Spread / Highest target
+56.43%
Low Price Target
120.00USD
Spread / Lowest Target
-16.57%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Citigroup
Goldman Sachs
Jefferies & Co.
BNP Paribas
UBS
RBC Capital Markets
Stifel Nicolaus
Baird
Wells Fargo Securities
JPMorgan Chase
Truist Securities
TD Cowen
Argus
BofA Securities
Morgan Stanley
Cantor Fitzgerald
William Blair & Co.
Melius Research
Barclays
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
143.83USD
Average target price
153.60USD
Spread / Average Target
+6.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LDOS Stock
  4. Consensus Leidos Holdings, Inc.